Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Autor: Christopher T. Su, J. Christine Ye

Publikováno v: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-18 (2021)

Abstract The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical appr

Externí odkaz: https://doaj.org/article/6cf63a061d784f869babf80b36a25ea1

Adapting Preclinical Benchmarks for First‐in‐Human Trials of Human Embryonic Stem Cell‐Based Therapies

Autor: Gaia Barazzetti, Samia A. Hurst, Alexandre Mauron

Publikováno v: Stem Cells Translational Medicine, Vol 5, Iss 8, Pp 1058-1066 (2016)

As research on human embryonic stem cell (hESC)‐based therapies is moving from the laboratory to the clinic, there is an urgent need to assess when it can be ethically justified to make the step from preclinical studies to the first protocols invol

Externí odkaz: https://doaj.org/article/6562fc4f9ab748f4b570772e58bff84b

Designing an Approach to Fluorescently Imaging MDSCs in vivo; First in Human Trials: Analyzing Ethical Standards

Technical Project The technical project is focused on designing an approach to fluorescently imaging Myeloid Derived Suppressor Cells (MDSCs). These immune cells are of particular interest because they are expressed at elevated levels in mice followi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74562ae97868f6f6c3ed2584e0941268

Cell-based interventions in utero: time to reconsider

Autor: Nancy M. P. King, Ana S. Iltis

Publikováno v: Frontiers in Pharmacology, Vol 5 (2014)

Externí odkaz: https://doaj.org/article/3da8e12faddf400fb9f310d53497c04c

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

Autor: Anna Durigova, Alice Cuenant, Krisztian Homicsko, Marie Vinches, Nadia Hayaoui, Marie Alexandre, Marie Viala, Luca Gianni, Diego Tosi, Céline Gongora, Caroline Mollevi

Publikováno v: British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩
British journal of cancer, vol. 118, no. 5, pp. 679-697

International audience; BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined.METHODS: We identifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03f0a204474d74cee7ad53b33df4109
https://hal.umontpellier.fr/hal-02292921